Darifenacin in the treatment of overactive bladder.
Antimuscarinic drug therapy has been shown to be effective in the management of patients with symptoms of the overactive bladder syndrome (OAB), but the bothersome antimuscarinic adverse effects of dry mouth, constipation, somnolence and blurred vision often affect compliance with medication. The development of bladder selective M3 specific antagonists offers the possibility of increasing efficacy whilst minimising adverse effects. The M3 specific antagonist solifenacin has recently been marketed, and darifenacin will soon be available. The purpose of this article is to review the pharmacology and clinical trial data available for darifenacin, in addition to examining its role in the treatment of the OBS.
Parsons
M
M
Department of Urogynaecology, 3rd Floor, Golden Jubilee Wing, King's College Hospital, London, UK. mparsons@doctors.org.uk
Robinson
D
D
Cardozo
L
L
D000042:Absorption; D001572:Benzofurans / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D002493:Central Nervous System Diseases / Q000139:chemically induced; D004347:Drug Interactions; D004361:Drug Tolerance; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D018727:Muscarinic Antagonists / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D011976:Receptors, Muscarinic / Q000378:metabolism; D016896:Treatment Outcome; D001745:Urinary Bladder Diseases / Q000188:drug therapy*; D014555:Urination Disorders / Q000188:drug therapy*
D001572:Benzofurans; D018727:Muscarinic Antagonists; D011759:Pyrrolidines; D011976:Receptors, Muscarinic; C101207:darifenacin